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Introduction and Risk Assessment  
In developed countries Breast Cancer (BC) occurs in one out of eight women during her lifetime, 
estimating the life expectancy of 85 years. About 10% of BC are associated with genetic risk factors, 
essentially mutations of BRCA1 and BRCA2, however but the majority of BC are sporadic. Risk 
factors for BC are primarily related to age and to estrogen exposure (early menarche, late menopause, 
nulliparity, use of exogenous hormones), in addition high risk population also include women with 
atypical hyperplasia, and patients with ductal or lobular carcinoma in situ. 
The lifetime cumulative risk of breast cancer for women with BRCA1 or BRCA2 mutations is very 
high ranging from 45 to 65%, this population has an elevated ovarian cancer risk as well1. The ovarian 
cancer estimated lifetime risks is 36-46% and 10-27% in BRCA1 and BRCA2 mutation carriers, 
respectively. Therefore for these women a close surveillance is suggested as well as medical and 
surgical options, including chemoprevention, bilateral salpingo-oophorectomy and mastectomy.  
Outside of genetic risk factors, for general population, it’s important to identify women at high risk 
of breast cancer: patients with previous thoracic RT < 30 y of age, women diagnosed with lobular 
carcinoma in situ, women with an estimated 5-year breast cancer risk ≥1.7%2. Several mathematical 
models to estimate this risk have been proposed, currently the most used is the National Cancer 
Institute (NCI) Breast Cancer Risk Assessment Tool which is a modified version of the Gail model that 
consider age, race, age at first pregnancy, family history and history of atypical hyperplasia; 
individuals with a 5-year risk of 1.66% or greater are considered at risk3. All the models have a limited 
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reliability and, as a matter of fact, up to 60% of BC occurs in women with no known risk factors; the 
available models do not include some risk factors such as obesity, diet, mammographic density and use 
of HRT. A higher accuracy could be obtained by incorporating information on genotypes as well.  
A recent report published on the new England journal of medicine4 underlines the importance of 
atypical hyperplasia as an independent factor for the inclusion of patients in chemoprevention 
programs. Atypical hyperplasia is a high-risk benign lesion that is found in approximately 10% of 
biopsies with benign findings. In studies with long-term follow-up, atypical hyperplasia has been 
shown to confer a relative risk for future breast cancer of 4. Another large cohort study at the Mayo 
Clinic5 published on 2014, confirms the cumulative high risk of breast cancer among women with 
atypical hyperplasia. Indeed, 25 years after a biopsy showing atypical hyperplasia, breast cancer 
(either in situ or invasive) developed in 30% of the women, with greater numbers of foci associated 
with a higher risk. Hartman and co. conclude suggesting that absolute risk data about women 
diagnosed with atypical hyperplasia should be used instead of models to describe breast-cancer risk in 
this population. Guidelines for high-risk women should be updated to include women with atypical 
hyperplasia. Analyses of data from the subgroup of women with atypical hyperplasia were performed 
in four of the placebo-controlled trials (NSABP P-1, MAP.3, IBIS-I, and IBIS-II). A total of 2009 
women with atypical hyperplasia were randomly assigned to receive an active agent or placebo in 
these trials. Relative-risk reductions in the atypical hyperplasia subgroup ranged from 41 to 79%, 
which suggested an even greater benefit than in the total population treated with active agent in these 
trials.  
Women with a life expectancy of ≥10 years and no diagnosis or history of breast cancer who are 
considered to be at increased risk for breast cancer based on any of the above-mentioned assessments, 
should receive individualized counseling to decrease breast cancer risk. Strategies for prevention of 
breast cancer include: lifestyle factors (avoidance of obesity, maintaining physical activity, 
moderation in alcohol intake), chemoprevention therapy with risk-reduction agents and risk-reduction 
surgery2.  
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Risk reduction mastectomy (RRM)  
Retrospective analyses with median follow-up periods of 13 to 14 years have indicated that bilateral 
risk–reducing mastectomy decreased the risk of developing breast cancer by approximately 90% in 
moderate- and high-risk women and in known BRCA1/2 mutation carriers6. Further results from 
smaller prospective studies with shorter follow-up support the conclusion that RRM provides a high 
degree of protection against breast cancer in women with a BRCA1/2 mutation. A recent meta-analysis 
including 2635 patients, demonstrated a significant risk reduction of breast cancer incidence in 
BRCA1 and BRCA2 mutation carriers receiving RRM (HR 0.07; 95 % CI 0.01-0.44; p = 0.004).  
In the 2007 guidelines issued by the Society of Surgical Oncology, indications for bilateral 
prophylactic mastectomies in Patients without a Cancer Diagnosis included: BRCA mutations or 
other genetic susceptibility genes, strong family history with no demonstrable mutation, histological 
risk factors (including atypical ductal or lobular hyperplasia, or lobular carcinoma in situ confirmed on 
biopsy); a further indication was a difficult surveillance7. The position Statement states that rarely, 
bilateral prophylactic mastectomies may be warranted for an exceptional patient with no family history 
or high-risk histology such as patient with extremely dense fibronodular tissue that is difficult to 
evaluate with standard breast imaging, several prior breast biopsies for clinical and/or mammographic 
abnormalities, and strong concern about breast cancer risk. In the same guidelines, potential 
indications for prophylactic contralateral mastectomy in patients with a current or previous diagnosis 
of breast cancer were: risk reduction (see indications as listed above), difficult surveillance (patients 
with clinically and mammographically dense breast tissue or diffuse indeterminate microcalcifications 
in the contralateral breast), or reconstructive issues (symmetry/balance).   
The 2017 NCCN Breast Cancer Risk Reduction Panel supports the use of RRM for carefully selected 
women at high risk for breast cancer who desire this intervention, exclusively considering BRCA1/2 
or other genetic mutations and previous history of LCIS2. There are no data regarding RRM in women 
with prior mantle radiation exposure. As regard Atypical hyperplasia, the Society of Surgical 
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Oncology recognizes it as a possible but not routine indication for bilateral prophylactic mastectomy7. 
The recent report published on the new England Journal of Medicine on Atypical hyperplasia and 
possible surgical Risk Reduction Interventions, concludes that, in current practice, with minimal data 
available on this topic and with chemopreventive agents for risk reduction available, atypical 
hyperplasia is generally not an indication for prophylactic mastectomy32.  
Women considering RRM should first have appropriate multidisciplinary consultations, a clinical 
breast examination and bilateral mammogram if not performed within the past 6 months. If results are 
normal, women who choose RRM may undergo the procedure with or without immediate breast 
reconstruction. Axillary node assessment has limited utility at the time of RRM. Women undergoing 
RRM do not require an axillary lymph node biopsy unless breast cancer is identified on pathologic 
evaluation of the mastectomy specimen. Following RRM, for monitoring breast health, women should 
continue with annual exams of the chest and the reconstructed breast because there is still a small 
residual risk of developing breast cancer. Mammograms are not recommended in this situation2. 
 
Bilateral risk-reducing salpingo-oophorectomy (RRSO)  
The absence of reliable methods of early detection and the poor prognosis associated with advanced 
ovarian cancer have lent support for the performance of bilateral risk-reducing salpingo-oophorectomy 
(RRSO) that decreases the risk of developing ovarian and fallopian cancer by 85-95% in BRCA1/2 
mutation carriers when performed before age 508. RRSO is also reported to reduce by approximately 
50% the risk for breast cancer in BRCA mutation carriers when performed in premenopausal age. The 
results of several studies suggest that RRSO may be associated with a greater reduction in breast 
cancer risk for BRCA1 mutation carriers compared with BRCA2 mutation carriers9-10.  
The decreased hormonal exposure following surgical removal of the ovaries is the basis for the 
reductions in breast cancer risk after RRSO; results from Eisen et al suggest the reductions in breast 
cancer risk is greater when the surgery is performed in younger women: (OR 0.41 (95% CI, 0.25-0.68) 
for RRSO performed at age 40 years or younger versus odds ratio 0.47 (95% CI, 0.28-0.80) for RRSP 
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performed in carriers aged 41-50 years). Non significant risk reduction of breast cancer was found for 
women aged 51 years or older10. Data are limited about the optimal age for RRSO. Considering that 
the mean age at diagnosis of ovarian cancer is 50.8 year for BRCA1/2 mutation carriers11, current 
guidelines for ovarian cancer risk management recommended bilateral salpingo-oophorectomy at the 
completion of childbearing or by age 35 to 402. Considering the slight advance of the diagnosis in 
BRCA 1 carriers than in BRCA 2, in the first group of patients, the RRSO could be proposed as soon 
as possible after the completion of childbearing, delaying the surgery after 40 years only after careful 
consideration of risks and benefits. In BRCA2 mutated patients, instead, the action may be brought 
between 40 and 50 years considering the progressive reduction of the protective effect against breast 
cancer12. 
Following prophylactic salpingo-oophorectomy a 1-4.3% residual risk for a primary peritoneal 
carcinoma in BRCA1 and BRCA2 mutation carriers still exists13. It cannot be excluded that in some 
cases peritoneal carcinoma foci are actually metastases of sub-clinical disease that was present at the 
time of surgery (occult carcinomas), so that undiagnosed cancers at the time of surgery will be 
considered primary peritoneal cancer when they become clinically apparent. Possibly fewer peritoneal 
cancers will be diagnosed after salpingo-oophorectomy if the comprehensive pathology review of the 
specimens is performed on all patients14. Fisch et al in paper based on a series of 159 female BRCA1 
or BRCA2 carriers who underwent prophylactic oophorectomy, showed that 2-10% of BRCA1/2 
carriers who undergo prophylactic salpingo-oophorectomy will be found to have occult carcinomas if 
the ovaries and the tubes are rigorously examined. No cancers were detected among women who had 
the operation at age 39 or younger15. The conclusion is that a rigorous operative and pathologic 
protocol for RRSO increases the detection rate of occult ovarian malignancy in BRCA mutation 
carriers, influencing the postoperative management whit additional staging, chemotherapy, and follow-
up in affected women. Also the peritoneal lavage cytology can detect occult carcinoma at the time of 
RRSO16 and should always be performed2. The additional benefit of concurrent hysterectomy is not 
clear. Even if careful ligation of the fallopian tube at the uterine origin is performed, a small portion of 
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interstitial fallopian tube in the cornua of the uterus is left in situ if hysterectomy is not performed, 
however, in the largest study on fallopian tube cancer to date, 92% of cancers originated in the distal 
or midportion of the tube. The concurrent hysterectomy, can simplify HRT allowing estrogen only 
supplementation and can reduce the endometrial cancer risk associated with Tamoxifen treatment for a 
previous breast cancer12. However the risk and benefits of concomitant hysterectomy should be 
discussed with each individual woman. As the majority of BRCA-associated ovarian cancers appear to 
originate in the fallopian tube, some Authors propose prophylactic salpingectomy; data on short- and 
long-term outcomes of this prophylactic surgery is limited and there are no studies directly comparing 
prophylactic salpingectomy with bilateral salpingo-oophorectomy for BRCA mutated women. A 
clinical trial led by Leblanc et al is currently recruiting young BRCA mutation carriers for radical 
fimbriectomy (NCT016808074), but it is not expected to be complete until 201917. A two-stage 
procedure has been proposed: bilateral salpingectomy with delayed oophorectomy to prevent the 
adverse consequences of premature menopause. Know et al developed a Markov Monte Carlo 
simulation model to compare three strategies for risk reduction in women with BRCA mutations: 
bilateral salpingo-oophorectomy; bilateral salpingectomy; bilateral salpingectomy with delayed 
oophorectomy. The model estimates the number of future breast and ovarian cancers and 
cardiovascular deaths attributed to premature menopause with each strategy: bilateral salpingo-
oophorectomy offers the greatest risk reduction for breast and ovarian cancer, but when considering 
quality-adjusted life expectancy, bilateral salpingectomy with delayed oophorectomy is a cost-
effective strategy and may be an acceptable alternative for those unwilling to undergo immediate 
bilateral salpingo-oophorectomy18. Finally some authors proposed the tubal ligation as a feasible 
option to reduce the risk of ovarian cancer in women with BRCA mutations who have completed 
childbearing. Four main mechanisms are invoked: a screening effect, the alteration of ovarian function, 
a mechanical barrier to the ascent of endometrial or proximal fallopian tube cells into the peritoneal 
cavity and the prevention of retrograde transport of carcinogenic substances from the vagina. A meta-
analysis of 13 studies shows a reduced risk of epithelial ovarian cancer by 34%. The protective effect 
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of tubal ligation was confirmed even in a subgroup of women 10–14 years after the procedure. The 
risk reduction was confirmed for the endometrioid and serous cancers but not for mucinous19. 
 
Treatment of menopausal symptoms in BRCA mutation carriers 
The absence of reliable methods of early detection and the poor prognosis associated with advanced 
ovarian cancer have lent support for the performance of bilateral risk reduction RRSO, however there 
are many concerns and worries about the resulting premature menopause.  
The most common symptoms are: vasomotor symptoms (hot flashes, night sweats, palpitations), 
vaginal dryness, sexual dysfunction, cognitive dysfunction, poor sleep and tiredness. Women who 
were premenopausal at the time of surgery experienced a worsening of hot flashes, night sweats and 
sweating and a decline in sexual function 1 year after surgery. Menopausal disorders are more severe if 
RRSO is performed in pre menopausal women  than in post menopausal women20.  
Premenopausal oophorectomy is also associated with an increased risk of osteopenia, osteoporosis 
and fracture. Following oophorectomy, there is an increased prevalence of osteoporosis within three 
to six years of surgery, the loss of trabecular bone has been reported to be as high as 20% during the 
first 18 months following surgery. Several recent cross-sectional studies have examined bone health 
after salpingo-oophorectomy in women with a BRCA mutation. Cohen et al. published a study of 226 
BRCA carriers after salpingo-oophorectomy21: among women who underwent surgery before the age 
of 50 years, high rates of osteopenia (62%) and osteoporosis (9%) were reported. The 2010 Canadian 
guidelines for diagnosis and management of osteoporosis proposes bone density measurement with 
DXA at the time of salpingo-oophorectomy and again 1–2 years after surgery; the timing of further 
bone density measurements should be individualized based on the results of these two measurements; 
to prevent osteoporosis¸ a recommended daily intake of 1500 mg calcium from dietary and 
supplemental sources and supplementation with 800 IU/day of vitamin D daily is suggested. In women 
with premature menopause Hormone Replacement Therapy (HRT), if not contraindicated, is advised 
to preserve bone mineral density, however the duration of use is not clear2.  
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Bilateral oophorectomy has also been shown to be a risk factor for coronary heart disease. A positive 
association between bilateral oophorectomy and increased risk of cardiovascular disease has been 
observed in a number of observational studies, including the Nurse’s Health Study (rate ratio 2.2) and 
the Mayo Clinic Cohort of Oophorectomy and Aging (HR 1.4). A recent study22 links BRCA1 gene 
function with cardiovascular function, ( RCA1 gene products work to prevent DNA damage). The loss 
of BRCA1 in cardiomyocytes may results in adverse cardiac remodeling, poor ventricular function and 
increased mortality in response to ischemic or genotoxic stress. Therefore BRCA1-mutated women 
may be at an increased risk for cardiovascular disease. Even if there are no clinical studies to date to 
evaluate this issue. Also in this context HRT may mitigate the increase in cardiovascular risk 
associated with surgical menopause. 
Several studies show that short-term HRT use does not negate the protective effect of RRSO on 
subsequent breast cancer risk in BRCA1/2 mutation carriers23. In a matched case-control study of 472 
postmenopausal women with a BRCA1 mutation, Eisen et al. examined whether or not the use of HRT 
was associated with subsequent risk of breast cancer24. The adjusted OR for breast cancer associated 
with ever use of HRT compared with never use was 0.58 (95% CI 0.35 - 0.96; P = .03), they concluded 
that HRT use was not associated with increased risk of breast cancer; indeed, in BRCA1 mutated 
women, it was associated with a decreased risk. In a recent review Marchetti and al25 conclude that 
HRT generally reduces symptoms related to surgical menopause, short-term HRT seems to improve 
quality of life and does not seem to have an adverse effect on oncologic outcomes in BRCA1 and 
BRCA2 mutation carriers without a personal history of breast cancer. The 2013 NICE guidelines 
recommends HRT for women with no personal history of breast cancer, including BRCA1 or BRCA2 
mutation carriers, having had bilateral salpingo-oophorectomy before their natural menopause. They 
should take combined HRT or Estrogens only depending on having the uterus or not, until the time 
they would have expected natural menopause. 
Estrogen therapy, however, is contraindicated for breast cancer survivors26. The Stockholm trial27 
was prematurely stopped in 2003 when the parallel HABITS trial28 reported a higher recurrence rate in 
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breast cancer patients who received systemic estrogens compared to women treated with placebo. At 4 
years of follow-up, the HABITS study still found an increased risk of recurrence29 whereas a recent 
updated analysis of the data from the Stockholm trial at 10.8 years of follow-up did not show any 
excess of recurrence risk30. An alternative compound to conventional estrogen/progestogen treatment, 
tibolone, was tested versus placebo in the LIBERATE trial, showing a significant superiority to 
placebo in reducing vasomotor symptoms and improving sleep quality, sexual behaviour, mood and 
attraction, but unfortunately also a significant increase in the recurrence rate31.  
Because of this concern, research efforts have focused on non-hormonal drugs to alleviate 
climacteric symptoms. Several substances have been tested: some of them give similar results to 
placebo, that in itself provides a response in around 20-30% of women, others have shown promising 
results.  
 
Conclusions 
Women with a life expectancy ≥10 years and no diagnosis/history of breast cancer who are considered 
to be at increased risk for breast cancer, should receive counseling to decrease breast cancer risk, 
considering: lifestyle factors, therapy with risk-reduction agents, risk-reduction surgery (in BRCA1/2 
mutation carriers). 
Bilateral risk reducing mastectomy decreases the risk of developing breast cancer by at least 90%; it 
should be proposed to carefully selected women at high risk for breast cancer considering BRCA1/2 or 
other genetic mutations and previous history of LCIS. In current practice, atypical hyperplasia is not 
an indication for prophylactic mastectomy. 
Bilateral risk reducing salpingo-oophorectomy decreases the risk of developing ovarian and fallopian 
cancer by 85-95% and breast cancer by 50% in BRCA1/2 mutation carriers when performed in 
premenopausal age. Peritoneal washing should be performed at surgery and pathologic assessment 
should include fine sectioning of the ovaries and fallopian tubes. The additional benefit of concurrent 
hysterectomy is not clear at the time. In women with no personal history of breast cancer short-term 
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HRT use does not negate the protective effect of RRSO on subsequent breast cancer risk and it should 
be offered until the time of expected natural menopause. 
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